



Canadian involvement in PrEP work

Madzouka Kokolo
MSc(candidate)



Ottawa, Ontario, Canada, 20 November 2009

Acknowledgements

- ICAD Workshop organizers
- My mentors: Dr. D.W. Cameron, Dr. D.A. Fergusson
- ICAD Workshop participants

Canadian involvement in PrEP clinical research

- University of Manitoba
Dr. Allan Ronald
PartnersPrEP: co-investigator / Kampala, Uganda
On-going. (<http://clinicaltrials.gov/ct2/show/NCT00557245>)
- University of Toronto
Dr. Darrell Tan
Survey: use of off-label PrEP among MSMs
In planning. (personal communication)

http://www.umanitoba.ca/faculties/medicine/units/medical_microbiology/academic_docs07_08/research_development_projects.doc

3

Canadian authors of PrEP papers

- McGill University AIDS Centre, Montreal, Quebec
Mark Wainberg
- McMaster University, Hamilton, Ontario
Edward Mills
- University of Toronto, Toronto, Ontario
James Orbinski, Jerome Singh, Ross Upshur, Kumanan Wilson
Darrell Tan
- University of Ottawa, Ottawa, Ontario
Madzouka Kokolo

4

Canadian community-based organizations involved in PrEP

- Canadian AIDS Society (CAS)
- Global Campaign for Microbicides (GCM)
- Interagency Coalition on AIDS and Development (ICAD)
- Canadian AIDS Treatment Information Exchange (CATIE)
Trends and Issues for Advancing Prevention, Care, Treatment And Support Through Knowledge Exchange (2009)

http://www.catie.ca/pdf/Canada/HIV-in-Canada_ES.pdf

5

Federal Initiative to Address HIV/AIDS in Canada

- *Leading Together: Canada Takes Action on HIV/AIDS (2005-2010)*
“increase and accelerate research on HIV vaccines and increase research to improve prevention, care, treatment, women-controlled methods of prevention, microbicides and the means to prevent mother-to-child transmission”
Canadian Public Health Association, 2005 (page 49)
- Canadian HIV Vaccine Initiative
Sarazin V, Milsom P. *Potential synergies between HIV vaccines, microbicides and pre-exposure prophylaxis*
Poster presentation, AIDS Vaccine 2009, Paris
Retrovirology 2009, 6(Suppl 3):P223

http://www.leadingtogether.ca/pdf/Leading_Together.pdf

<http://www.retrovirology.com/content/6/S3/P223>

6

PrEP research funding in Canada

- HIV/AIDS Research Initiative, Strategic Plan 2008-2013

“ Biomedical and clinical research in prevention technologies such as vaccines and microbicides, as well as culturally sensitive behavioural and social intervention studies and analyses of legal and policy issues are required.

*Related research may include (...) investigations that lead to the discovery of new strategies such as microbicides or **pre- and post exposure prophylaxis** (...) ”*

Canadian Institutes for Health Research, September 2008 (page 10)

http://www.cihr-irsc.gc.ca/e/documents/hiv_strat_plan_0813_e.pdf

7

QUESTIONS & COMMENTS

For further information

- **Federal Initiative to Address HIV/AIDS in Canada**
<http://www.phac-aspc.gc.ca/aids-sida/fi-if/index-eng.php>
- **Canadian HIV Vaccine Initiative**
<http://www.chvi-icvv.gc.ca/>
- **Canadian AIDS Society (CAS)**
<http://www.cdn aids.ca/>
- **Global Campaign for Microbicides (GCM)**
<http://www.global-campaign.org/>
- **Interagency Coalition on AIDS and Development (ICAD)**
<http://www.icad-cisd.com/>

9

For further information

- **Tan DH, Ota K, Fisman DN.** The Impact of Tenofovir-based HIV Pre-Exposure Prophylaxis on Life Expectancy and Quality-Adjusted Life Expectancy: A Markov Cohort Model. 18th Annual Canadian Conference on HIV/AIDS Research, 2008 April 23-26 (Abstract O041).
- **Kokolo M, Fergusson DA, Cameron DW.** Pre-exposure prophylaxis: a rising star in HIV prevention research? 18th Annual Canadian Conference on HIV/AIDS Research, 2008 April 23-26 (Abstract P181).
- **Derdelinckx I, Wainberg MA, Lange JM, Hill A, Halima Y, Boucher CA.** Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. *PloS Med.* 2006 Nov;3(11):e454.
- **Mills E, Siegfried N.** Cautious optimism for new HIV/AIDS prevention strategies. *Lancet.* 2006 Oct 7;368(9543):1236.
- **Grant RM, Wainberg MA.** Chemoprophylaxis of HIV infection: moving forward with caution. *J Infect Dis.* 2006 Oct 1;194(7):874-6.

10

For further information

- **Mills** EJ, Singh S, **Singh** JA, **Orbinski** JJ, Warren M, **Upshur** RE. Designing research in vulnerable populations: lessons from HIV prevention trials that stopped early. *BMJ*. 2005 Dec 10;331(7529):1403-6.
- Grant RM, Buchbinder S, Cates W Jr, Clarke E, Coates T, Cohen MS, Delaney M, Flores G, Goicochea P, Gonsalves G, Harrington M, Lama JR, MacQueen KM, Moore JP, Peterson L, Sanchez J, Thompson M, **Wainberg** MA. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. *Science*. 2005 Sep 30;309(5744):2170-1.
- **Singh** JA, **Mills** EJ. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? *PLoS Med*. 2005 Sep;2(9):e234.
- **Mills** E, Rachlis B, Wu P, Wong E, Wilson K, Singh S. Media reporting of tenofovir trials in Cambodia and Cameroon. *BMC Int Health Hum Rights*. 2005 Aug 24;5:6.
- **Mills** E. Tenofovir trials raise ethical issues. *HIV AIDS Policy Law Rev*. 2005 Aug;10(2):31-2.
- Youle M, **Wainberg** MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. *J Int Assoc Physicians AIDS Care (Chic Ill)*. 2003 Jul-Sep;2(3):102-5.
- Youle M, **Wainberg** MA. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? *AIDS*. 2003 Apr 11;17(6):937-8.